Skip to main content
Loading

Mitotech

October 17, 2023
Franciscan B
Metabolic Diseases
Company Description: Mitotech Ltd is a UK-based clinical stage biotechnology company developing mitochondria targeted drugs for a variety of neurodegenerative and metabolic diseases such as Obesity, NASH, Miltiple Sclerosis, Alzheimer's and Friedreich's Ataxia. Our products are based on a calss of novel small molecules that inhibit ferroptosis at the mitochondria level.
Speakers
Anton Petrov, COO - Mitotech

Country

United Kingdom

Website

http://mitotechpharma.com

CEO/Top Company Official

Natalia Perekhvatova, CEO

Lead Product in Development

Oral formulation of SkQ1 - mitochondria targeted ferroptosis inhibitor - for treatment of NASH/Obesity, MS and Friedreich Ataxia

Development Phase of Primary Product

Pre-Clinical

BIO DOUBLE HELIX SPONSOR

BIO HELIX SPONSOR

CONFERENCE SPONSORS